Company intelligence / Profile preview

Synedgen

Claremont, California, United States

Ownership: Private
Development stage: Phase 1

Overview

Synedgen’s lead program MIIST305 has shown preclinical efficacy in mitigating GI acute radiation syndrome injury in animal models. The company has received significant federal funding to advance this candidate through proof-of-concept studies toward FDA approval. Its wound care portfolio includes two commercialized products with strong safety profiles supported by DoD grants

Therapeutic areas: GastroenterologyPulmonologyOphthalmologyDermatologyInfectious Diseases
Modalities: Proprietary polysaccharide derivativesglycochemistry-based therapeuticstopical and oral formulations
Industry: Biotech

Drug pipeline

6 assets

SYGN313

Preclinical

5 more assets in the full pipeline.

Request access →

Partnerships

BARDA/U.S. Department of Health & Human Services Biomedical Advanced Research and Development Authority ($119 million contract)U.S. ArmyDARPA support for product development/grants

Beyond the preview

Go deeper on Synedgen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synedgen.

Explore the full profile